Results for the quarter and nine months ended December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medico Intercontinental reported Q3FY26 standalone revenue from operations of Rs. 1,275.12 lakhs, up about 12% from Rs. 1,142.82 lakhs in Q3FY25. However, nine-month (9M FY26) standalone revenue dropped sharply to Rs. 3,863.74 lakhs from Rs. 5,188.54 lakhs in 9M FY25, a decline of roughly 25%. Standalone profit after tax was Rs. 61.15 lakhs for Q3 (vs Rs. 54.66 lakhs) and Rs. 175.95 lakhs for 9M (vs Rs. 203.27 lakhs), an 8% YoY drop. On a consolidated basis, results include 5 subsidiaries and a joint venture (Medico Lab); subsidiaries alone posted a net loss of about Rs. 1,040.74 lakhs for the 9M period, dragging consolidated profits sharply lower. The auditor (V. Goswami & Co) issued an unmodified review opinion. The company also changed its accounting policy for the joint venture from proportionate consolidation to the equity method (Ind AS 28), and prior-period consolidated figures were restated accordingly.
The sharp 9M revenue decline and subsidiary-level losses are negatives for shareholders, while the policy change restatement makes year-on-year comparisons less straightforward. Q3 showed modest improvement but is unlikely to lift sentiment given the weak 9M trajectory and group-level losses.